Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Tsao, Anne S.; Lindwasser, O. Wolf; Adjei, Alex A.; Adusumilli, Prasad S.; Beyers, Matthew L.; Blumenthal, Gideon M.; Bueno, Raphael; Burt, Bryan M.; Carbone, Michele; Dahlberg, Suzanne E.; Perrot, Marc de; Fennell, Dean A.; Friedberg, Joseph S.; Gill, Ritu R.; Gomez, Daniel R.; Harpole, David H.; Hassan, Raffit; Hesdorffer, Mary; Hirsch, Fred R.; Hmeljak, Julija; Kindler, Hedy L.; Korn, Edward L.; Liu, Geoffrey; Mansfield, Aaron S.; Nowak, Anna K.; Pass, Harvey I.; Peikert, Tobias; Rimner, Andreas; Robinson, B. W.; Rosenzweig, Kenneth E.; Rusch, Valerie W.; Salgia, Ravi; Sepesi, Boris; Simone, Charles B.; Sridhara, Rajeshwari; Szlosarek, Peter W.; Taioli, Emanuela; Tsao, Ming Sound; Yang, Haining; Zauderer, Marjorie G.; Malik, Shakun

doi:10.1016/j.jtho.2018.08.2036

Cited by 97 publications

(67 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent clinical trial demonstrated that the addition of bevacizumab improves survival over the use of the platinum‐doublet alone, although this regimen has not been approved by the FDA to date. However, even with aggressive trimodality or bimodality therapy, the median survival for resectable pleural mesothelioma remains at 17 to 25 months and, for unresectable mesothelioma, it is 9 to 12 months . It is crucial to identify novel, well defined targets.…”

Section: Treatmentmentioning

confidence: 99%

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Carbone

Adusumilli

Alexander

et al. 2019

CA A Cancer J Clinicians

Self Cite

377

488

View full text Add to dashboard Cite

Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high-resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1-asssociated protein 1 (BAP1) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment. CA Cancer J Clin 2019;69:402-429.

show abstract

Section: Treatmentmentioning

confidence: 99%

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Carbone

Adusumilli

Alexander

et al. 2019

CA A Cancer J Clinicians

Self Cite

377

488

View full text Add to dashboard Cite

show abstract

“…47 Even with such an aggressive chemotherapy, OS for unresectable mesothelioma remains ≤12 months. 48 Given the limitations in the efficacy of existing cytotoxic chemotherapy in MPM and recent advances in tumor immunology across various malignancies, ICIs have been investigated for the treatment of unresectable mesothelioma. A single-arm, Durvalumab with First-line Chemotherapy in Mesothelioma study examined treatment efficacy after adding durvalumab, a PD-L1 inhibitor, to CPPD/PEM, in 54 patients with untreated, unresectable MPM 49 (table 1).…”

Section: Icis In the First-line Settingsmentioning

confidence: 99%

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma

Hotta

Fujimoto

2020

J Immunother Cancer

View full text Add to dashboard Cite

Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM.

show abstract

“…Together, these issues have conspired to prevent the type of progress for surgery-based MPM treatments that the specialists would like to see and the patients deserve. 25 A significant limitation is represented by the authors being exclusively from North America, which might incompletely align with the opinions of mesothelioma surgeons in European or worldwide. This joint NCI-IASLC-MARF task force work is a proposal to establish a suggested standardized approach for surgery and a standard set of data to collect for patients undergoing surgery-based treatment for MPM.…”

Section: Discussionmentioning

confidence: 98%

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce

Friedberg

Culligan

Tsao

et al. 2019

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

This article is a joint effort arising from a task force formed at a National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting, held at the NIH in March 2017. Malignant pleural mesothelioma remains one of the most virulent and recalcitrant malignancies, still considered incurable, and in desperate need of clinical trials in order to make progress for our patients. Although not standard of care, there is compelling evidence that a select subgroup of mesothelioma patients benefit from a surgery-based multimodal approach. As it is not possible to achieve a microscopically complete resection with mesothelioma, there appears to be no role for surgery alone. Thus, it is anticipated that significant strides in the surgery-based treatment of this cancer will require trials that determine which complementary treatments best augment the cytoreductive efficacy of surgery. Although

show abstract

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Cited by 97 publications

References 106 publications

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce

Contact Info

Product

Resources

About